Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...

Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

An artificial intelligence-aided program accurately predicted 5-year survival for early breast cancer on the basis of a tumor's location. (JCO Clinical Cancer Informatics) Actor D ...

Cuts to the CDC and FDA, experts say, could reverse hugely successful campaigns to cut cigarette smoking rates and curb teen vaping.

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

A key lung cancer congress held in Europe disclosed that a new breakthrough has been made by Hengrui Pharmaceuticals, a ...

In celebration of a decade of powerful advocacy and progress, LUNG FORCE Heroes?individuals personally impacted by lung cancer?will once again travel from across the country to Washington, D.C., for ...

Public awareness of the link between drinking alcohol and an elevated risk of cancer has grown since last fall, with more than half of Americans now saying that regularly consuming alcohol increases ...

New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...